

# Data Submission User's Guide

Date	Version Number	Name	Activity
12/02/2022	1.0	Theagis Lynch	Document Creation

## **Table of Contents**

I.	Overview of System	4
II.	Site and User Registration	4
Sit	es	4
Us	ers	5
III.	Logging into the System	6
IV.	Accessing the Main IQA Linearity Page	7
V.	Registering a Cytometer1	15
VI.	Submitting Results1	6

### I. Overview of System

This users' guide describes the features found in the IQA CD4 web-based system for a site participating in the IQA CD4 program.

The browsers currently supported by the application are:

- Microsoft Edge Version 105 and up
- Chrome Version 106.0 and up
- Firefox Version 105.0 and up.

**Note:** Internet Explorer is not supported by this application.

The IQA CD4 program is administered by the Duke Human Vaccine Institute (DHVI). In this program, sites are provided two samples for their analysis. The web application will be used by sites to submit their data for the IQA CD4 program. The system allows registration of sites and users at the approval of IQA management. Users will be associated with sites and sites will be assigned to specific IQA programs in which they are enrolled.

After a site submits their results, the results will be analyzed by the Duke Human Vaccine Institute's biostatisticians. A report will be uploaded which will contain the evaluation of the CD4 results. This report will inform each site about the accuracy of their results.

Within the IQA CD4 proficiency page, users can view both completed and active trials. Within an active trial, users can enter results and download site-specific reports. For completed trials, users will only be able to view/download reports but will not have the ability to edit documents.

The system will also enable sites to view their site's cumulative performance rating.

## II. Site and User Registration

#### Sites

- To register a new site, IQA management will need to know the site's name, lab number and a primary contact email address. This information should be provided to <a href="mailto:raul.louzao@duke.edu">raul.louzao@duke.edu</a>
  - The primary contact will receive all email communication from the IQA system.
- IQA management will enter this information into the web-based application to begin the enrollment process.
- The primary contact will receive an email from the IQA system with a link to the IQA system.
- Once the primary user is registered in the system, the user can reset their password and enter in additional site and user information.
- The primary user can also add email addresses for other users connected to the site.

• Site-designated users will receive an email from the system to complete registering their id to the system.

#### Users

- IQA management will grant access to the IQA Web system.
- The user will receive a registration email once the user has been registered. **The following is an example of the email the user will receive:**

To: Site user < <u>siteuser@duke.edu</u> > Subject: Welcome to IQA Data Webpage	
Welcome to the online IQA Data Webpage. Please use the link below to register. <u>https://iqaapp-test.dhvi.duke.edu/sign_up?signup_token=0aa1cf20-2ac1-013b-27ca-005056adbedd</u> Thank you. IQA	

- The user will access the registration page via the emailed link. To register, the user will need to set up a password.
- The following is an example of the screen that will appear after the link is accessed:

An NIH, NIAID, DAIDS Program	
Register	
Please choose whether you are a Duke user or external user. <ul> <li>Non-Duke External User</li> <li>Duke User</li> </ul>	
Email	
First Name	
Last Name	
Primary Phone Number	
Password	
Password confirmation	
Register	

## III. Logging into the System

- The IQA system can be accessed through https://iqaapp.dhvi.duke.edu after completing the initial registration.
- The log-in page will prompt you to enter your email address and password.
- If a user fails to enter his/her password after four consecutive attempts, the account will be locked for 15 minutes. The user account will automatically unlock after 15 minutes.
- If a user forgets their password, select "Forgot/Reset your password" where the user will enter their email address.
  - Once you enter the user's email address, a link to reset your password will be sent to you via email.
- The selection "Sign in with DHE Credentials" is for Duke-based users only.

• The following page is an example of the Sign in page.

Immunology Quality Assessment Program An NIH, NIAID, DAIDS Program	U r	Duke Human Vaccine Institut
Sign In		
Email		
Password Forgot/Reset your password		
Sign in Sign in with DHE credentials	IQA is a U.S. Government information System. Use recording, and auditing, Unauthorized use is prohibit	of the system indicates consent to monitoring, ed and subject to criminal and civil penalties.
Contact Us	SciMeD SOLUTIONS	lqa Prod1 - 2.24

## **IV.** Data Entry

- Once a trial becomes active, an email will be sent to the site informing them about the trial.
- If results are not submitted by the trial end date, the results will be counted as late.
- The following is an example of the email the user will receive when a trial is available for submitting results:

Sent: Tuesday, November 15, 2022 3:06 PM	
To: Site user <site.user@duke.edu></site.user@duke.edu>	
Subject: - Your IQA Trial Begins Today	
This email confirms the shipment of IQA of samples for Trial 13160 of the CD4 Immune Mo	onitoring program.
The Closing Date for this Trial is: 11/17/2022 12:00 AM.	
If the samples do not reach your center in the expected delivery period, please contact IQ	А.
To access the data entry system, please go to the IQA online trial webpage at <a href="https://iqaaluga.cc">https://iqaaluga.cc</a>	pp-test.dhvi.duke.edu/proficiency test enrollments/23016.
If you have any questions about using the web service, or have a problem accessing the sit	te, please contact:
Mr Raul Louzao, MPA	
Immunology Quality Assessment	
Program Manager	
NIH-NIAID Division of AIDS	
Denny Lab - RTP Parmer	
27 Alexandria Way	
Durham, NC 27703	
Tel: 919-684-5861	

- After the site receives the email announcement, the user will have access to the IQA CD4 Proficiency program upon system log in.
- Once the proficiency test is active, the user will see a list of all active and completed trials. The following is an example of the program page displaying an active trial:

ame –		bu	nchiga@gmail.com   Site.Info.L
		191	nchiqa@ginali.com   <u>Site into</u>   j
	Signed in success	sfully.	anar anar anar an
QA CD4			
Please enter results for all the requir CD4 team. Any questions feel free t	ed fields. Once you are satisfied with your entries, o contact us.	you need to press the complete button to s	ubmit the results to the IQA
Tel: 919-943-1444			
email: <u>raul.louzao@duke.edu</u>			
Active Trials			
<u>Trial CD4 Test Trial 2</u>			
Completed Trials			
No Completed Trials			
Current Site Certification			
Cite	Castification	Dascad?	Trial

• Click on the name of the active trial. The next page (trial page) will display a row with your site name. The trial start date and the trial end date for submitting results will appear on the page. **The following is an example of this page**:

An NIH, NIAID, DAIDS Pro	sment Program gram			U	Duke Human \	Vaccine Institute
ams 🗸					<u>lynchiqa@gma</u>	<u>ail.com   Site Info   Log O</u>
QA CD4 Trial CD4	lest Trial	2 (Active	)			
Site	Assay	Questionnaire	Start Date	End Date	Results	Reports
LYN001 - IQA Site CD4	1		12/06/2022	12/13/2022	Due: 12/13/2022	
Back to IQA CD4						
		•	11			

• The following is an example of the page that will be displayed after a user clicks on their site's name:

Immunology Quality Assessment Program An NIH, NIAID, DAIDS Program	<b>Uuke</b> Human Vaccine Institute
Programs 👻	<u>lynchiqa@gmail.com   Site Info   Log Out</u>
IQA CD4 Trial CD4 Test Trial 2 - LYN001 - IQA Site CD4	Assay Run 1
INSTRUCTIONS         RESULTS         REPORTS         COMMUNICATION/FEEDBACK           Due 12/13/2022	
Back to Trial CD4 Test Trial 2     Back to IQA CD4	

• To enter test results, click on the "Results" tab. The following page will appear after clicking on the "Results" tab:

An NIH, NIAID, DAIDS Prog	ment Program ram	<b>U Duke</b> Human Vaccine Instit
<sup>rams</sup> → Trial CD4 Test Trial 2	Results for LYN001 - IQA	lynchiqa@gmail.com   Site Info   Lo Site CD4
INSTRUCTIONS RESULTS COMM	INICATION/FEEDBACK	
Main Immunology Analysis	Unreported Phenotyping	
Questionnaire Received	Fill out the Questionnaire	
Methodology Information Date Samples Prepared	Flow Cytometry Information Flow samples analyzed at	
Preparation V	Cytometer	1
Platform 🖲 Single 🔿 Double	Single platform 🗸 🗸	
Save Complete		

- The user will enter information on the tabs (Main, Immunology Analysis) located on the Results page. The "Unreported Phenotyping" tab will be used to report values not reported for samples.
- The following fields are required on the Main tab page:
  - $\circ$  Received -
  - Date Samples Prepared
  - Flow Samples analyzed at
  - Preparation
  - Cytometer

Note: The platform defaults to Single but can be changed by clicking the Double checkbox.

- The "Single platform" field is optional.
- If "Double" is selected for the platform, the following fields are required on the Main tab page:
  - Date Samples Prepared
  - Flow Samples analyzed at
  - $\circ$  Preparation
  - o Cytometer
  - o Platform

- Complete the questionnaire if one exists by selecting the text "Fill out the Questionnaire".
- Click on the Immunology Analysis tab to enter your sample results. **The following is an** example of the Immunology Analysis page:

12202       12201         D45BRIGHT+CD14.	ain Immunology Anal	vsis Unreporte	ed Phenotyping	
D45BRIGHT+CD14-		122202	122201	
anufacturer of MAb   vermixed MAb   vermixed MAb   vermixed MAb   D3+ %   D3+ Abs   anufacturer of MAb   vermixed MAb <td>D45BRIGHT+CD14-</td> <td></td> <td></td> <td></td>	D45BRIGHT+CD14-			
remixed MAb 🖗	anufacturer of MAb	~	~	
ye for CD45BRIGHT  v v v ye For CD14- v v ye For CD14- v v v D3+ % D3+ Abs D3+ Abs D3+ Abs D3+ Abs D3+ CD3+ v v v D3+/CD4+ % D3+/CD4+ Abs anufacturer of MAb v v v emixed MAb v v v v v v emixed MAb v v v v v v emixed MAb v v v v v v v v v emixed MAb v v v v v v v v v v v v v v emixed MAb v v v v v v v v v v v v v v v v v v v	emixed MAb 🖉 📄			
ye For CD14-       v       v         D3+ %	ve for CD45BRIGHT	~	~	
D3+ %	e For CD14-	~	~	
D3+ %				
D3+ Abs	03+ %			
anufacturer of MAb remixed MAb ye For CD3+ D3+/CD4+ % D3+/CD4+ Abs anufacturer of MAb vemixed MAB vemix	D3+ Abs			
remixed MAb ♥ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	anufacturer of MAb	~	~	
ye For CD3+          D3+/CD4+ %          D3+/CD4+ Abs          anufacturer of MAb          ye For CD3+          ye For CD3+          ye For CD4+	emixed MAb 🖉 📄			
D3+/CD4+ % D3+/CD4+ Abs anufacturer of MAb ↓ ↓ ↓ remixed MAb ♥ remixed MAB ♥ remi	e For CD3+	~	~	
D3+/CD4+ % D3+/CD4+ Abs anufacturer of MAb remixed MAb ♥ /e For CD3+ /e For CD4+ >23/CD9+ %				
D3+/CD4+ Abs	D3+/CD4+ %			
anufacturer of MAb  verified	03+/CD4+ Abs			
remixed MAb ♥	anufacturer of MAb	~	~	
ye For CD3+  ve For CD4+  v	emixed MAb 🖉 📄			
ve For CD4+ ✓ ✓	/e For CD3+	~	~	
	/e For CD4+	~	~	
J3+/CD8+ %	D3+/CD8+ %			

- All fields on the Immunology Analysis page are optional.
- Each field is validated when the user enters a value into a field. If the user enters an invalid value, an error message will be issued and the value can be corrected.
  - % values must be entered to 2 decimal places. If 2 decimal places are not available, use trailing zeroes to achieve 2 decimal places.
  - Absolute count values must be a whole number. If a whole number is not available, round to the nearest whole number.

• The following is an example of the Unreported Phenotyping page:

INSTRUCTIONS RESULTS REPORTS COMMUNICATION/FEEDBACK	
Main Immunology Analysis Unreported Phenotyping	
Select a Sample V Select a Parameter V Select an Explanation V Rectangular Snp Unreported Phenotype	
Save Complete	

- After the user enters their results, they can click the "Save" or the "Complete" button. By pressing "Save", a copy of the results will be saved in the system, but it will not be recorded as final until you mark your results as "Complete".
  - Selecting "Save" will save a copy of the results data
  - Selecting "Complete" will both save your results data and submit your results as final.
- After the data results have been submitted successfully, the date the site submitted their results will be displayed on the trial page. The following is an example of the page after the questionnaire and the results have been submitted.

QA CD4 Trial CD4 1	est Tria	I 2 (Active)	)			
Site	Assay Run	Questionnaire	Start Date	End Date	Results	Reports
LYN001 - IQA Site CD4	1	Submitted 12/06/2022	12/06/2022	12/13/2022	Completed 12/06/2022	
O Rock to 104 CD4						

• If changes are needed after submitting your results, IQA management can unlock your results, which will allow modifications to be made. The results will display the word, "Modified" under the Completed date if the results were changed and re-submitted. **The following page shows the results were modified:** 

A CD4 Trial CD4	Test Tria	al 2 (Active)				
Site	Assay Run	Questionnaire	Start Date	End Date	Results	Reports
YN001 - IQA Site CD4	1	Submitted 12/06/2022	12/06/2022	12/13/2022	Completed 12/06/2022 Modified 12/09/2022	

## V. Retrieving Site Specific Report

- After the results have been submitted, the IQA management team will complete their analysis of the site's results, and a site-specific report will be generated and uploaded to the website.
- Once the report has been uploaded, an email will be sent to the primary site user informing them the report is ready to be reviewed. The following is an example of the report available email:

	*TEST* - IQA CD4 Trial Trial CD4 Test Trial 2 - Report available Index x			₽	Ľ
?	no-reply⊜iqaapp-test.dhvi.duke.edu ≹ tome →	12:53 PM (15 minutes ago)	☆	¢	:
	A report has been generated for your lab in IQA CD4 Trial Trial CD4 Test Trial 2. You can access the report on the IQA website				
	If you have any questions, or have a problem accessing the site, please get in touch with:				
	Mr Raul Louzao, MPA				
	Immunology Quality Assessment				
	Program Manager				
	NIH-NIAID Division of AIDS				
	Denny Lab - RTP Parmer				
	27 Alexandria Way				
	Durham, NC 27703				
	Tel: 919-684-5861				
	Fax: 919-681-8251				
	The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes heishe might have received it due to an addressing error, by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke policies on confidentiality and/or with the approval of th	is requested to notify the se re sender.	nder im	media	ely

• When the report is available for review, the text under the report column will state "Report Available". **The following is an example:** 

Site	Run	Questionnaire	Start Date	End Date	Results	Reports
YN001 - IQA Site CD4	1	Submitted 12/06/2022	12/06/2022	12/13/2022	Completed 12/06/2022	Report Available

- To access the report, select the "Reports" tab.
- After the report has been uploaded, the user can view/download the report by selecting the file. **The following is an example of the Report tab:**

Immunology Quality Assessment Program An NIH, NIAID, DAIDS Program	<b>UV Duke</b> Human Vaccine Institute
Programs 👻	lynchiqa@gmail.com   Site Info   Log Out
IQA CD4 Trial CD4 Test Trial 2 - LYN001 - IQA Site CD4	Assay Run 1
INSTRUCTIONS RESULTS REPORTS COMMUNICATION/FEEDBACK	

## VI. Current Site Performance Ratings

• The site user will be able to see their site's current performance rating based on the last trial assessment. The ratings will appear on the IQA CD4 program page. **The following is an example of the performance rating displayed for a site:** 

CD4 team. Any questions feel free to contact	us.	es, you need to press	the complete button to submit the results to the IQ.
Tel: 919-943-1444			
email: raul.louzao@duke.edu			
Active Trials			
No Active Trials			
Completed Trials			
<u>Trial CD4 Test Trial 2</u>			
Current Site Certification			
Site	Certification	Passed?	Trial
LYN001 IQA Site CD4	Satisfactory	0	Trial CD4 Test Trial 2